A method for detecting antimicrobial resistant bacteria from environmental samples

IN595684BActive Publication Date: 2026-07-16INDIAN INST OF TECHNOLGOY ROORKEE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
IN202411040598
Authority / Receiving Office
IN · IN
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-05-24
Publication Date
2026-07-16
Estimated Expiration
2044-05-24

AI Technical Summary

Technical Problem

Current methods for detecting antimicrobial resistant bacteria in environmental samples are labor-intensive, costly, and require specialized laboratories, leading to inconsistent data and limited availability due to reliance on laboratory-based surveillance and lack of awareness about globally accepted protocols.

Method used

A simple, convenient, and cost-effective chromogenic test assay that involves multistep filtration and the use of Nitrocefin to detect antimicrobial resistant bacteria, which can be performed at the site of collection and does not require bacterial growth media, allowing for rapid and reliable detection of drug-resistant bacterial populations.

Benefits of technology

The method enables quick, culture-free detection of antimicrobial resistant bacteria in environmental samples, reducing detection time to 30 minutes and achieving a detection limit of at least 105 CFU/ml, making it suitable for field use and providing consistent data without the need for specialized facilities or expert personnel.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to a method for detecting antimicrobial resistant bacteria from environmental samples within 30 min after adding nitrocefin on filter which are selected from ‘cellulose ester’ based and biodegradable filters to maintain an environment friendly process. Further, the detection limit of said method is at least 105 CFU / ml of the sample collected wherein the samples collected are resistant against the antibiotics selected from trimethoprim, kanamycin, cephalothin, meropenem, cefotaxime, ampicillin, oxacillin, ciprofloxacin and a combination can be detected. The method disclosed herein is quick, requires less technical expertise and cost effective. wherein said method detects the presence of drug resistant bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Description:FIELD OF THE INVENTION

[0001] The present disclosure broadly relates to the field of microbiology, specifically within the subfield of antimicrobial resistance research. More particularly, the present disclosure provides a method for detecting antimicrobial resistant bacteria from environmental samples, which is quick, requires less technical expertise and cost effective.BACKGROUND OF THE INVENTION

[0002] Background description includes information that may be useful in understanding the present invention. It is not an admission that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.

[0003] Environmental samples, including wastewater, soil, and river / lake water, serve as significant sources for the escalating emergence of drug-resistant bacteria due to improper discharge. These bacteria can enter the environment and, over time, pose serious health risks. It is imperative to recognize the gravity of Antimicrobial Resistance (AMR), which is spreading rapidly.

[0004] AMR not only impacts human health but also jeopardizes the fundamental pillars of a country's or continent's economic status by causing harm in four domains: animal, food, and environmental. It is crucial to address this issue promptly. Researchers across the globe has reported some other sources of environmental AMR spread is Livestock discard, Agricultural sludge and manure Heavy metals and Aaquaculture.

[0005] India and Bangladesh have a longstanding record of topping the charts in terms of antimicrobial resistance. This phenomenon may be attributed to inadequate maintenance and awareness. The combination of self-medication and indiscriminate use of antibiotics exerts selection pressure on microbes. The untreated drainage systems allow wastewater from households, hospitals, shops, and animal farms to mix with larger water bodies, progressively transforming them into reservoirs of resistant genes. Key contributors to this issue include agricultural sludge, improper waste discharge from animal farms where antibiotics are excessively used, and remnants from the expanding aquaculture industry.

[0006] It is well reported that the ‘Resistome’ present in sludge consists of those genes even after decomposition. Ganges and Yamuna are two major rivers of India and are found to have contaminated with drug resistant pathogens (blaNDM-1 and blaOXA-48) due to having several inlets across the way. 20-30% of the total municipal wastes have been treated in waste treatment facilities which still needs to be treated to remove the pathogenic organisms. The E. coli resistant from 3rd gen Cephalosporin collected from domestic wastewater, domestic wastewater along with hospital acquired waste and hospital acquired wastewater alone was found 25%, 70% and 95%.

[0007] However, none of the method disclosed in the prior arts focuses on achieving precisely replicable and consistent data which, in turn, poses a challenge due to spatial variations in microbe concentrations. The inconsistency in data is also attributed to a lack of awareness regarding the adoption of globally accepted protocols, such as maintaining the Clinical and Laboratory Standards Institute (CLSI) standards 2020, which remain a gold standard. Moreover, existing surveillance methods for emerging antimicrobial resistant pathogens are predominantly laboratory-based, making them expensive, labour-intensive, slow, and reliant on transportation. These methods necessitate execution by trained professionals in dedicated laboratories, and the high costs associated with fully equipped facilities limit their availability for AMR detection.

[0008] Hence, there is a dire need to fill the gaps present in the prior art by developing a simple, convenient, and reliable chromogenic test assay for the detection and diagnosis of Antimicrobial Resistant (AMR) bacteria in samples which would significantly simplify and enhance the process, contributing to a healthier and more efficient approach. OBJECTS OF THE INVENTION

[0009] An objective of the present invention is to provide a method for detecting antimicrobial resistant bacteria from environmental samples

[0010] Another objective of the present invention is to provide a method a simple, convenient, and reliable chromogenic test assay for the detection and diagnosis of Antimicrobial Resistant (AMR) bacteria in samples.

[0011] Another objective of the present invention is to provide an easy, quick and cost-effective method to detect the bacteria in an environmental sample.SUMMARY OF THE INVENTION

[0012] This summary is provided to introduce a selection of concepts in a simplified form that are further described below in Detailed Description section. This summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used as an aid in determining the scope of the claimed subject matter.

[0013] An aspect of the present disclosure is to provide a method for detecting antimicrobial resistant bacteria from environmental samples comprising the steps of:i. collecting the soil sample suspected of containing drug resistant bacteria; and resuspending the soil sample in sterile water; / waste waterii. performing multistep filtration comprising:iii. a 1st filter characterized as a coarse filter having the size ranging from 1.0mm-100um to sieve out larger sized particles including sand, pebbles or a combination thereof;iv. a 2nd filter characterized as a filter having the size ranging from 50?m -05?m size range including small particles, small fibres or a combination thereof;v. a 3rd filter characterized as a bacterial filter having the size ranging from 0.45?m pore size to collect the bacterial population present in the samples collected;vi. implying a vacuum pump to concentrate the bacteria on the 3rd filter;vii. collecting the filtrate obtained from step (c);viii. adding 1mM Nitrocefin in a range of 100?l to 200 ?l to the bacterial filter followed by incubating this filter at room temperature up to 10 minutes to generate the change in colour from yellow to red;ix. evaluating the intensity of the final colour (red) of the filtrate on 3rd filter paper, wherein colour intensifies with increasing drug resistant bacterial population.wherein 1000 ml of sample is required for liquid samples and 200-500 gm is required for solid samples; wherein colour generation is dependent on the drug resistant bacterial population on the filter paper;wherein said method is culture free and can be performed at the spot of collection; andwherein all the steps of said method is executed at room temperature.

[0014] Various objects, features, aspects and advantages of the inventive subject matter will become more apparent from the following detailed description of preferred embodiments.FIGURES OF THE INVENTION

[0015] FIG. 1 shows the drug resistance profile from samples collected from different parts of Roorkee.

[0016] FIG. 2 discloses the growth of environment samples with and without Ampicillin (10 mcg / ml) measured at 600 nm for 18 hours.

[0017] FIG. 3 displays the schematic of the Process developed for testing the AMR Bacteria in Environmental Samples.

[0018] FIG. 4 depicts the principle of working of the colorimetric Dye used in the tester.

[0019] FIG. 5 shows the IMP-1 Producing E. coli showing AMR on Filter 3 after the Procedure shown in FIG. 3.

[0020] FIG. 6 shows the AMR detection by colorimetric assay on filter 03DETAILED DESCRIPTION OF THE INVENTION

[0021] The following is a detailed description of embodiments of the disclosure. The embodiments are in such detail as to clearly communicate the disclosure. However, the amount of detail offered is not intended to limit the anticipated variations of embodiments; on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the present disclosure as defined by the appended claims.

[0022] Unless the context requires otherwise, throughout the specification which follow, the word “comprise” and variations thereof, such as, “comprises” and “comprising” are to be construed in an open, inclusive sense that is as “including, but not limited to.”

[0023] As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the content clearly dictates otherwise. It should also be noted that the term “or” is generally employed in its sense including “and / or” unless the content clearly dictates otherwise.

[0024] In some embodiments, the numbers expressing quantities of ingredients, properties such as concentration, reaction conditions, and so forth, used to describe and claim certain embodiments of the invention are to be understood as being modified in some instances by the term “about.” Accordingly, in some embodiments, the numerical parameters set forth in the written description are approximations that can vary depending upon the desired properties sought to be obtained by a particular embodiment. In some embodiments, the numerical parameters should be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of some embodiments of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as practicable.

[0025] The recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it is individually recited herein.

[0026] All processes described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided with respect to certain embodiments herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.

[0027] The headings and abstract of the invention provided herein are for convenience only and do not interpret the scope or meaning of the embodiments.

[0028] The following discussion provides many example embodiments of the inventive subject matter. Although each embodiment represents a single combination of inventive elements, the inventive subject matter is considered to include all possible combinations of the disclosed elements. Thus, if one embodiment comprises elements A, B, and C, and a second embodiment comprises elements B and D, then the inventive subject matter is also considered to include other remaining combinations of A, B, C, or D, even if not explicitly disclosed.

[0029] All publications herein are incorporated by reference to the same extent as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Where a definition or use of a term in an incorporated reference is inconsistent or contrary to the definition of that term provided herein, the definition of that term provided herein applies and the definition of that term in the reference does not apply.

[0030] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member can be referred to and claimed individually or in any combination with other members of the group or other elements found herein. One or more members of a group can be included in, or deleted from, a group for reasons of convenience and / or patentability. When any such inclusion or deletion occurs, the specification is herein deemed to contain the group as modified thus fulfilling the written description that follows, and the embodiments described herein, is provided by way of illustration of an example, or examples, of particular embodiments of the principles and aspects of the present disclosure. These examples are provided for the purposes of explanation, and not of limitation, of those principles and of the disclosure.

[0031] It should also be appreciated that the present invention can be implemented in numerous ways, including as a system, a method or a device. In this specification, these implementations, or any other form that the invention may take, may be referred to as processes. In general, the order of the steps of the disclosed processes may be altered within the scope of the invention.

[0032] Various terms as used herein are shown below. To the extent a term used in a claim is not defined below, it should be given the broadest definition persons in the pertinent art have given that term as reflected in printed publications and issued patents at the time of filing.

[0033] An aspect of the present disclosure is to provide a method for detecting antimicrobial resistant bacteria from environmental samples comprising the steps of:i. collecting the environmental sample suspected of containing drug resistant bacteria; and resuspending the soil sample in sterile water; or water sample is used directly.ii. performing multistep filtration comprising:iii. a 1st filter characterized as a coarse filter having the size ranging from 1.0mm-100um to sieve out larger sized particles including sand, pebbles or a combination thereof;iv. a 2nd filter characterized as a filter having the size ranging from 50?m -05?m size range including small particles, small fibres or a combination thereof;v. a 3rd filter characterized as a bacterial filter having the size ranging from 0.45?m pore size to collect the bacterial population present in the samples collected;vi. implying a vacuum pump to concentrate the bacteria on the 3rd filter;vii. collecting the filtrate obtained from step (c);viii. adding 1mM Nitrocefin in a range of 100?l to 200 ?l to the bacterial filter followed by incubating this filter at room temperature up to 10 minutes to generate the change in colour from yellow to red;ix. evaluating the intensity of the final colour (red) of the filtrate on 3rd filter paper, wherein colour intensifies with increasing drug resistant bacterial population.wherein 1000 ml of sample is required for liquid samples and 200-500 gm is required for solid samples; wherein colour generation is dependent on the drug resistant bacterial population on the filter paper;wherein said method is culture free and can be performed at the spot of collection; andwherein all the steps of said method is executed at room temperature.

[0034] In an embodiment, said method detects the presence of drug resistant bacteria within 10 min after adding nitrocefin on filter obtained from step (c) of claim 1(ii).

[0035] In an embodiment, said filters are selected from ‘cellulose ester’ based and biodegradable filters to maintain an environment friendly process.

[0036] In an embodiment, the detection limit of said method is at least 105 CFU / ml of the sample collected.

[0037] In an embodiment, the the samples collected are resistant against the antibiotics selected from trimethoprim, kanamycin, cephalothin, meropenem, cefotaxime, ampicillin, oxacillin, ciprofloxacin and a combination can be detected

[0038] In an embodiment, said steps are completed within 30 minutes.

[0039] In another aspect, the invention disclosed in the present invention is capable of monitoring the AMR pathogens from environmental samples efficiently. The data will be needed in policy making for medical advisory boards as a precaution. Further, the method disclosed in the present invention provides a tight control on the reaction specificity.

[0040] In another aspect, the Environmental BL-tester disclosed in the present invention is a culture free technique means; no bacterial growth medium is needed to detect the presence of AMR pathogens, as the samples will be unprocessed.

[0041] It is an aspect of the present invention that the invention disclosed is completely lab-free, i.e, the experiments could be done at any place required. The only reagent is the colour producing compound nitrocefin, that also could be carried inside a container in smaller tubes. Thus, this could be done anytime, anywhere and the result could be analysed by naked eye as the colour change takes place in visible range (bright yellow to dark red) in presence of pathogenic bacteria.

[0042] In an aspect, the amount of sample is not a problem at all, because environmental samples (soil, water) are available in greater amounts and could be taken anytime in larger quantities.

[0043] In an aspect, the colorimetric experiment of Environmental BL-tester disclosed in the present invention doesn’t require any expert personnel to perform.

[0044] In another aspect, the major aim of the present invention detection time is one of the most essential parameters and our aim is to detect the presence of pathogens withing smaller time fame possible. Data from our samples has showed that 30 min is the detection time on an average. In other words, colour generation on the filter could be visualized and result could be drawn within 30 min.

[0045] In another aspect, the present invention showed that the minimum detection range is 105 CFU / ml from environmental samples. This also corresponds to the CLSI guideline of detecting an MIC value of pathogens. More the merrier, but 105 CFU / ml must be needed for the colour generation within 30 min.

[0046] While the foregoing describes various embodiments of the disclosure, other and further embodiments of the disclosure may be devised without departing from the basic scope thereof. The invention is not limited to the described embodiments, versions or examples, which are included to enable a person having ordinary skill in the art to make and use the invention when combined with information and knowledge available to the person having ordinary skill in the art.EXAMPLES

[0047] The present invention is further explained in the form of following examples. However, it is to be understood that the following examples are merely illustrative and are not to be taken as limitations upon the scope of the invention.

[0048] The present invention uses multiple type of samples selected from various places to analyses the sensitivity and broad coverage of the method. Accordingly, below samples were used (Table 1):

[0049] Sample 01 wastewater was collected from Solanipuram, Roorkee, Uttarakhand, India. The bacterial population had trimethoprim, kanamycin, cephalothin resistance majorly followed by meropenem, cefotaxime, ampicillin, and oxacillin resistance, even ciprofloxacin resistant cells were found to some extent (FIG. 1 & 2).

[0050] Sample 02 was another wastewater sample near Roorkee municipality. cefotaxime resistance was reflecting as a predominant determinant here followed by kanamycin, cephalothin, trimethoprim, oxacillin and meropenem. The sample was completely sensitive to ciprofloxacin (FIG. 1 & 2).

[0051] Sample 03 was collected from a drainage system near Railway station road, Bhagirath kunj. It was highly contaminated with several drug resistant bacteria. Majorly cefotaxime, ampicillin and trimethoprim resistance were predominating here as the curve represents. Among these antibiotics, ciprofloxacin was the least resistant antibiotic to the residing bacterial population (FIG. 1 & 2).

[0052] Sample 04 was taken from sewage near Preet Vihar colony. In this residential colony, ampicillin, meropenem, trimethoprim, kanamycin, cefotaxime resistant bacterial population represented in greater amounts with significant cephalothin, oxacillin, ampicillin resistance. But this population also sensitive to ciprofloxacin (FIG. 1 & 2).

[0053] Sample 05 represents the data collected from SDM chowk near HP petrol pump. Ampicillin, kanamycin, trimethoprim resistant bacteria were found majorly from the sample. Meropenem was still present but at a lesser extent but the bacteria resistant to Oxacillin and cephalothin could also be a matter of concern in this site. However, the bacterial population showed lesser extent of resistance towards cefotaxime and ciprofloxacin (FIG. 1 & 2).

[0054] Sample 06 was collected from Irrigation office area, Mahavir enclave, Bhagirath Kunj. Kanamycin and cephalothin, trimethoprim, oxacillin resistance was found in majority of bacteria and ampicillin, cefotaxime, meropenem also played a role here to develop bacterial resistance. Ciprofloxacin resistance was not found at this environment. Kanamycin resistance is surprisingly found higher compared to ampicillin, oxacillin and meropenem (FIG. 1 & 2).Table 01: Latitude and Longitude of collected samples are tabulatedSerial no Name Location GIS coordinate Lat Long1 Sample 01 Solanipuram 29.871571 77.9025082 Sample 02 Roorkee municipality 29.874683 77.8991043 Sample 03 Railway station road 29.853318 77.8713914 Sample 04 Preet Vihar colony 29.853318 77.8713915 Sample 05 SDM chowk HP petrol pump 29.861954 77.889086 Sample 06 Irrigation office area, Mahavir enclave. 29.852154 77.876601Example 1: Method of detecting the AMR in environmental samples

[0055] A fast, accurate and colorimetric assay to detect the presence of drug resistant pathogens by steps described below (FIG. 3, 4 & 6):1) Samples were collected from wastewater, soil, river / lake water, and used for the assay directly right in the field itself. Entire process was sample free means, bacterial growth media was not needed to conduct the assay. 1000 ml water was needed for liquid and 200-500 gm is needed to collect for solid samples.2) Solid samples were then dissolved in sterile water, vigorous shaking might need in case of hard or extremely dried samples.3) The dissolved sample was poured over the coarse filter (filter 01) to sieve out the grossly large particles (pebbles, large fibres, roots, visible insoluble fragments etc) and eventually were passed through filter 02 and finally the bacterial cells accumulated on filter 03 as it was having a 0.45?l of pore size. 4) Filter 03 was collected carefully after all the fluids were passed out and collected inside a container.5) 200 ?l of 1mM nitrocefin was added to filter 03 to observe the colour change. Presence of drug resistant bacteria changed the colour of nitrocefin from bright yellow to dark red due to a distinctly specific reaction (FIG. 5).6) All the filters used in this process were ‘cellulose ester’ based and biodegradable to maintain an environment friendly process.7) Detection limit was more than or equal to 105 CFU of bacterial cells per ml of samples collected.8) Detection time was less than or equal to 30 min, as optimized.9) The entire process was culture free and could be tested at the spot of collection.10) Entire process was executed at room temperature / outdoor temperature.

[0056] Overall, the invention solves technical problems by introducing a novel and improved method of detecting the AMR in bacteria present in environmental samples. The method disclosed is sensitive and

[0057] The foregoing examples are merely illustrative and are not to be taken as limitations upon the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the scope of the invention.ADVANTAGES OF THE INVENTION1. Environmental AMR surveillance: Environmental elements are gradually carrying an increased amount of pathogenic bacterial load due to an unscientific and irresponsible dumping of pathogens from health centres. Self-medication of antimicrobials is another major reason behind the selection pressure for these pathogens. This invention can monitor the AMR pathogens from environmental samples efficiently. The data may help in policy making for medical advisory boards as a precaution.2. Reaction specificity: ?-Lactam drugs are highly specific and reacts only with a single type of bacterial enzyme, present in every pathogenic bacterium. This specificity will provide a highly distinct type of chemical reaction. It will have a tight control on the reaction specificity.3. Culture free technique: Environmental BL-tester is a culture free technique means; no bacterial growth medium is needed to detect the presence of AMR pathogens, as our samples will be unprocessed.4. Lab fee method: This invention is totally lab-free means, the experiments could be done at any place required. The only reagent is the colour producing compound nitrocefin, that also could be carried inside a container in smaller tubes. Thus, this could be done anytime, anywhere and the result could be analysed by naked eye as the colour change takes place in visible range (bright yellow to dark red) in presence of pathogenic bacteria.5. Amount of sample: Amount of sample is not a problem at all, because environmental samples (soil, water) are available in greater amounts and could be taken anytime in larger quantities. 6. Easy to perform: Colorimetric experiment of Environmental BL-tester doesn’t require any expert personnel to perform. The invention has been planned in the simplest way possible, just collect the filter 03 after all the samples have been passed through and gently add 200 ?l of 1mM nitrocefin, then wait for the colour change from bright yellow to dark red. Intensity of the red colour correlates with the severity of the sample quality indicating toward a higher pathogenic bacterial population. Just add and wait, it’s that easy.7. Detection time and range: Detection time is one of the most essential parameters and our aim is to detect the presence of pathogens withing smaller time fame possible. Data from the samples has showed that 30 min is the detection time on an average. In other words, colour generation on the filter could be visualized and result could be drawn within 30 min. Detection range indicates the minimum concentration of bacterial cells could be detected by Environmental BL-tester. Our data showed that the minimum detection range is 105 CFU / ml from environmental samples. This also corresponds to the CLSI guideline of detecting an MIC value of pathogens. More the merrier, but 105 CFU / ml must be needed for the colour generation within 30 min.

Claims

, Claims:

1. A method for detecting antimicrobial resistant bacteria from environmental samples comprising the steps of:i. collecting the environmental sample suspected of containing drug resistant bacteria; and resuspending the soil sample in sterile water;ii. performing multistep filtration comprising:a) a 1st filter characterized as a coarse filter having the size ranging from 1.0mm-100um to sieve out larger sized particles including sand, pebbles or a combination thereof;b) a 2nd filter characterized as a filter having the size ranging from 50?m -05?m size range including small particles, small fibres or a combination thereof;c) a 3rd filter characterized as a bacterial filter having the size ranging from 0.45?m pore size to collect the bacterial population present in the samples collected.iii. implying a vacuum pump to concentrate the bacteria on the 3rd filter;iv. collecting the filtrate obtained from step (c);v. adding 1mM Nitrocefin in a range of 100?l to 200 ?l to the bacterial filter followed by incubating this filter at room temperature up to 10 minutes to generate the change in colour from yellow to red;vi. evaluating the intensity of the final colour (red) of the filtrate on 3rd filter paper, wherein colour intensifies with increasing drug resistant bacterial population.wherein 1000 ml of sample is required for liquid samples and 200-500 gm is required for solid samples; wherein colour generation is dependent on the drug resistant bacterial population on the filter paper;wherein said method is culture free and can be performed at the spot of collection; andwherein all the steps of said method is executed at room temperature.

2. The method as claimed in claim 1, wherein said method detects the presence of drug resistant bacteria within 10 min after adding nitrocefin on filter obtained from step (c) of claim 1(ii).

3. The method as claimed in claim 1, wherein said filters are selected from ‘cellulose ester’ based and biodegradable filters to maintain an environment friendly process.

4. The method as claimed in claim 1, wherein the detection limit of said method is at least 105 CFU / ml of the sample collected.

5. The method as claimed in claim 1, wherein the samples collected are resistant against the antibiotics selected from trimethoprim, kanamycin, cephalothin, meropenem, cefotaxime, ampicillin, oxacillin, ciprofloxacin and a combination can be detected.

6. The method as claimed in claim 1, wherein said steps are completed within 30 minutes.